Prazosin

Overview

Prazosin, sold under the brand name Minipress among others, is a medication used to treat high blood pressure, symptoms of an enlarged prostate, and nightmares related to post-traumatic stress disorder (PTSD). It is an α₁ blocker. It is a less preferred treatment of high blood pressure. Other uses may include heart failure and Raynaud syndrome. It is taken by mouth.[1][2] WP

Common side effects include dizziness, sleepiness, nausea, and heart palpitations. Serious side effects may include low blood pressure with standing and depression. Prazosin is a non-selective inverse agonist of the α₁-adrenergic receptors. It works to decrease blood pressure by dilating blood vessels and helps with an enlarged prostate by relaxing the outflow of the bladder. How it works in PTSD is not entirely clear.[1][2] WP

Prazosin was patented in 1965 and came into medical use in 1974. It is available as a generic medication. In 2021, it was the 183rd most commonly prescribed medication in the United States, with more than 2 million prescriptions.[1][3][4][5] WP

Uses, dosage and effects

Medical uses

Prazosin is active after taken by mouth and has a minimal effect on cardiac function due to its α₁-adrenergic receptor selectivity. When prazosin is started, however, heart rate and contractility can increase in order to maintain the pre-treatment blood pressures because the body has reached homeostasis at its abnormally high blood pressure. The blood pressure lowering effect becomes apparent when prazosin is taken for longer periods of time. The heart rate and contractility go back down over time and blood pressure decreases. WP

The antihypertensive characteristics of prazosin make it a second-line choice for the treatment of high blood pressure.[6] WP

Prazosin is also useful in treating urinary hesitancy associated with benign prostatic hyperplasia, blocking α₁-adrenergic receptors, which control constriction of both the prostate and urethra. Although not a first-line choice for either hypertension or benign prostatic hyperplasia, it is a choice for people who present with both problems concomitantly.[6] WP

During its use for urinary hesitancy in military veterans in the 1990s, Murray A. Raskind and colleagues discovered that prazosin appeared to be effective in reducing nightmares. Subsequent reviews indicate prazosin is effective in improving sleep quality and treating nightmares related to post-traumatic stress disorder (PTSD).[7][8] WP

Prazosin is used off-label in the treatment of insomnia for its sedative effects. Prazosin is an inverse agonist at α₁-adrenergic receptors; these receptors are expressed on dendrites that noradrenergic neurons synapse onto in the brain. Some of the noradrenergic pathways in the central nervous system form part of the ascending reticular activating system, which promotes arousal when stimulated. Prazosin inhibits the output neurons of the noradrenergic pathways in that system, in turn causing sedation.[9–12] WP

The drug is usually recommended for severe stings from the Indian red scorpion.[13][14][15] WP

Risks and side effects

Adverse effects

Common (4–10% frequency) side effects of prazosin include dizziness, headache, drowsiness, fatigue, weakness, palpitations, and nausea. Less frequent (1–4%) side effects include vomiting, diarrhea, constipation, edema, orthostatic hypotension, dyspnea, syncope, vertigo, depression, anxiety, nasal congestion, and rash. A very rare side effect of prazosin is priapism. One phenomenon associated with prazosin is known as the "first-dose response", in which the side effects of the drug—specifically orthostatic hypotension, dizziness, and drowsiness—are especially pronounced in the first dose.[16][17] WP

Orthostatic hypotension and syncope are associated with the body's poor ability to control blood pressure without active α-adrenergic receptors. The nasal congestion is exacerbated by changing body positions, because α₁-adrenergic receptors also control nasal vascular blood flow and alpha blockers inhibit this, in the same way that alpha-adrenergic agonists have the opposite effect of being a decongestant.[18][19] WP

Pharmacology

Pharmacodynamics

Prazosin is an α₁-blocker that acts as a non-selective inverse agonist at α₁-adrenergic receptors, including of the α1A-, α1B-, and α1D-adrenergic receptor subtypes. It binds to these receptors with affinity (Kᵢ) values of 0.13 to 1.0 nM for the α1Α-adrenergic receptor, 0.06 to 0.62 nM for the α1B-adrenergic receptor, and 0.06 to 0.38 nM for the α1D-adrenergic receptor. It has much lower affinity for the α₂-adrenergic receptors (Kᵢ = 210–5,012 nM for the α2A-adrenergic receptor, 13–676 nM for the α2B-adrenergic receptor, and 10–257 nM for the α2C-adrenergic receptor). The α₁-adrenergic receptors are found in vascular smooth muscle, where they are responsible for the vasoconstrictive action of norepinephrine. They are also found throughout the central nervous system. α₁-Adrenergic receptors have additionally been found on immune cells, where catecholamine binding can stimulate and enhance cytokine production.[20–27] WP

Pharmacokinetics

Prazosin has an onset of action of 30 to 90 minutes, the elimination half-life of prazosin is 2 to 3 hours, and its duration of action is 10 to 24 hours.[28][29] WP

Research

Insomnia

Prazosin has been said to be the only selective α₁-adrenergic receptor antagonist which has been used in the treatment of insomnia to any significant degree. It is used at doses of 1 to 12 mg for this purpose. The combination of prazosin and the beta blocker timolol may produce greater sedative effects than either of them alone.[9][10] WP

Cytokine storm

Prazosin has been shown to prevent death in animal models of cytokine storm. As a repurposed drug, prazosin is being investigated for the prevention of cytokine storm syndrome and complications of COVID-19 where it is thought to decrease cytokine dysregulation.[27][30][31][32] WP

Chemistry

Formula

C19H21N5O4 PC

CAS number

19216-56-9 PC

Molar mass (g/mol)

383.4 PC

IUPAC name (computed by PubChem)

[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(furan-2-yl)methanone PC

SMILES

COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC PC

InChIKey

IENZQIKPVFGBNW-UHFFFAOYSA-N PC

PubChem CID

4893

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

User reports

Pop culture

No references added yet.

Sources

1. Other Prazosin Hydrochloride Monograph for Professionals
2. Other British national formulary: BNF 76. 2018
3. Other Fischer J, Ganellin CR. Analogue-based Drug Discovery. 2006
4. Other The Top 300 of 2021
5. Other Prazosin - Drug Usage Statistics
6. Other Shen H. Illustrated Pharmacology Memory Cards: PharMnemonics. 2008
7. Journal / agency Zhang Y, Ren R, Sanford LD, Yang L, Ni Y, Zhou J, Zhang J, Wing YK, Shi J, Lu L, Tang X. The effects of prazosin on sleep disturbances in post-traumatic stress disorder: a systematic review and meta-analysis. Sleep Medicine. March 2020. doi:10.1016/j.sleep.2019.06.010 · PMID 31972510 · PMC6986268
8. Journal / agency Reist C, Streja E, Tang CC, Shapiro B, Mintz J, Hollifield M. Prazosin for treatment of post-traumatic stress disorder: a systematic review and meta-analysis. CNS Spectrums. August 2021. doi:10.1017/S1092852920001121 · PMID 32362287
9. Journal / agency Krystal AD. New Developments in Insomnia Medications of Relevance to Mental Health Disorders. The Psychiatric Clinics of North America. December 2015. doi:10.1016/j.psc.2015.08.001 · PMID 26600112 · PMC5972036
10. Journal / agency Atkin T, Comai S, Gobbi G. Drugs for Insomnia beyond Benzodiazepines: Pharmacology, Clinical Applications, and Discovery. Pharmacological Reviews. April 2018. doi:10.1124/pr.117.014381 · PMID 29487083
11. Journal / agency Iwańczuk W, Guźniczak P. Neurophysiological foundations of sleep, arousal, awareness and consciousness phenomena. Part 1. Anaesthesiol Intensive Ther. 2015. doi:10.5603/AIT.2015.0015 · PMID 25940332
12. Other Malenka RC, Nestler EJ, Hyman SE, Holtzman DM. Molecular Neuropharmacology: A Foundation for Clinical Neuroscience. 2015
13. Journal / agency Bawaskar HS, Bawaskar PH. Scorpion sting: A study of the clinical manifestations and treatment regimes. Current Science. 2008
14. Journal / agency Bawaskar HS, Bawaskar PH. Utility of scorpion antivenin vs prazosin in the management of severe Mesobuthus tamulus (Indian red scorpion) envenoming at rural setting. The Journal of the Association of Physicians of India. January 2007. PMID 17444339
15. Journal / agency Pandi K, Krishnamurthy S, Srinivasaraghavan R, Mahadevan S. Efficacy of scorpion antivenom plus prazosin versus prazosin alone for Mesobuthus tamulus scorpion sting envenomation in children: a randomised controlled trial. Archives of Disease in Childhood. June 2014. doi:10.1136/archdischild-2013-305483 · PMID 24550184
16. Journal / agency Minipress- prazosin hydrochloride capsule. 19 July 2021
17. Journal / agency Bhalla AK, Hoffbrand BI, Phatak PS, Reuben SR. Prazosin and priapism. British Medical Journal. October 1979. doi:10.1136/bmj.2.6197.1039 · PMID 519276 · PMC1596841
18. Journal / agency Riechelmann H, Krause W. Autonomic regulation of nasal vessels during changes in body position. European Archives of Oto-Rhino-Laryngology. 1994-01-01. doi:10.1007/BF00628425 · PMID 7917253
19. Journal / agency Johnson DA, Hricik JG. The pharmacology of alpha-adrenergic decongestants. Pharmacotherapy. 1993. doi:10.1002/j.1875-9114.1993.tb02779.x · PMID 7507588
20. Other Prazosin: Biological activity
21. Harm reduction site Prazosin
22. Other Prazosin Ligand page
23. Journal / agency Proudman R, Akinaga J, Baker JG. The affinity and selectivity of α-adrenoceptor antagonists, antidepressants and antipsychotics for the human α2A, α2B, and α2C-adrenoceptors and comparison with human α1 and β-adrenoceptors. Pharmacology Research & Perspectives. February 2022. doi:10.1002/prp2.936 · PMID 35224877 · PMC8882856
24. Other Prazosin: Clinical data
25. Journal / agency Day HE, Campeau S, Watson SJ, Akil H. Distribution of alpha 1a-, alpha 1b- and alpha 1d-adrenergic receptor mRNA in the rat brain and spinal cord. Journal of Chemical Neuroanatomy. July 1997. doi:10.1016/S0891-0618(97)00042-2 · PMID 9285356
26. Journal / agency Heijnen CJ, Rouppe van der Voort C, Wulffraat N, van der Net J, Kuis W, Kavelaars A. Functional alpha 1-adrenergic receptors on leukocytes of patients with polyarticular juvenile rheumatoid arthritis. Journal of Neuroimmunology. December 1996. doi:10.1016/s0165-5728(96)00125-7 · PMID 8982123
27. Journal / agency Konig MF, Powell M, Staedtke V, Bai RY, Thomas DL, Fischer N, Huq S, Khalafallah AM, Koenecke A, Xiong R, Mensh B, Papadopoulos N, Kinzler KW, Vogelstein B, Vogelstein JT, Athey S, Zhou S, Bettegowda C. Preventing cytokine storm syndrome in COVID-19 using α-1 adrenergic receptor antagonists. The Journal of Clinical Investigation. July 2020. doi:10.1172/JCI139642 · PMID 32352407 · PMC7324164
28. Journal / agency Packer M, Meller J, Gorlin R, Herman MV. Hemodynamic and clinical tachyphylaxis to prazosin-mediated afterload reduction in severe chronic congestive heart failure. Circulation. March 1979. doi:10.1161/01.cir.59.3.531 · PMID 761333
29. Other Prazosin
30. Journal / agency Staedtke V, Bai RY, Kim K, Darvas M, Davila ML, Riggins GJ, Rothman PB, Papadopoulos N, Kinzler KW, Vogelstein B, Zhou S. Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome. Nature. December 2018. doi:10.1038/s41586-018-0774-y · PMID 30542164 · PMC6512810
31. Other Preventing 'Cytokine Storm' May Ease Severe COVID-19 Symptoms
32. Other ClinicalTrialsGov NCT04365257 Prazosin to Prevent COVID-19 (PREVENT-COVID Trial) (PREVENT)

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0), PubChem (public domain). Each value links to the exact revision it came from.